Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Banting Postdoctoral Fellowship Program

Direct Payment

$140,000.00

Genomic prediction of response to PARP inhibition in breast cancer

EF 2013-14

Résumé
Although new treatments have helped improve the survival of breast cancer patients, the development of new therapies is challenging. Only a small number of therapeutic agents tested in the laboratory have demonstrated efficacy in patients. Laboratory models have commonly used cancer cells alone, but the growth of cancer cells and their response to therapy is affected by their surrounding microenvironment. My hypothesis is that response to therapy in breast cancer patients can be predicted in the laboratory using a microenvironment microarray. This technology consists of thousands of cell "spots" in one microscope slide, wherein cellular function can be measured with a fluorescent microscope. Several breast cancer cell lines, which are immortalized cancer cells, and various microenvironment proteins can be tested simultaneously. A gene signature that can predict therapeutic response will then be identified from breast cancer cells using sophisticated computer programs, and will be correlated with a gene signature obtained from patients. I will be focusing on a PARP inhibitor, a targeted therapeutic agent that affects DNA repair mechanisms. This inhibitor is also being tested in a clinical trial in locally advanced breast cancer patients prior to their surgery, called the I SPY2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis). In summary, this project tightly links results from laboratory experimentation with patient samples from a clinical trial. There is great potential that the microenvironment microarray will be an important pre-clinical model that will help identify which breast cancer patients will benefit from therapy
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
Oregon, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
296925
Name
Hassan Saima N
Region
Oregon
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Genomic prediction of response to PARP inhibition in breast cancer
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Breast Cancer; In-Vitro; Integrated Genomic Characterization; Microenvironment Model; Patients; Predictive Biomarkers
Abstract
Although new treatments have helped improve the survival of breast cancer patients, the development of new therapies is challenging. Only a small number of therapeutic agents tested in the laboratory have demonstrated efficacy in patients. Laboratory models have commonly used cancer cells alone, but the growth of cancer cells and their response to therapy is affected by their surrounding microenvironment. My hypothesis is that response to therapy in breast cancer patients can be predicted in the laboratory using a microenvironment microarray. This technology consists of thousands of cell "spots" in one microscope slide, wherein cellular function can be measured with a fluorescent microscope. Several breast cancer cell lines, which are immortalized cancer cells, and various microenvironment proteins can be tested simultaneously. A gene signature that can predict therapeutic response will then be identified from breast cancer cells using sophisticated computer programs, and will be correlated with a gene signature obtained from patients. I will be focusing on a PARP inhibitor, a targeted therapeutic agent that affects DNA repair mechanisms. This inhibitor is also being tested in a clinical trial in locally advanced breast cancer patients prior to their surgery, called the I SPY2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis). In summary, this project tightly links results from laboratory experimentation with patient samples from a clinical trial. There is great potential that the microenvironment microarray will be an important pre-clinical model that will help identify which breast cancer patients will benefit from therapy
Competitiondate
201310
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Hassan, Saima N
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~